U.S. markets close in 1 hour 53 minutes
  • S&P 500

    4,567.40
    +22.50 (+0.50%)
     
  • Dow 30

    35,757.79
    +80.77 (+0.23%)
     
  • Nasdaq

    15,220.43
    +130.23 (+0.86%)
     
  • Russell 2000

    2,310.84
    +19.57 (+0.85%)
     
  • Crude Oil

    83.94
    +0.18 (+0.21%)
     
  • Gold

    1,807.90
    +11.60 (+0.65%)
     
  • Silver

    24.59
    +0.15 (+0.60%)
     
  • EUR/USD

    1.1617
    -0.0028 (-0.24%)
     
  • 10-Yr Bond

    1.6340
    -0.0210 (-1.27%)
     
  • GBP/USD

    1.3773
    +0.0013 (+0.10%)
     
  • USD/JPY

    113.6700
    +0.2100 (+0.19%)
     
  • BTC-USD

    62,950.61
    +2,707.83 (+4.49%)
     
  • CMC Crypto 200

    1,505.27
    +1,262.59 (+520.27%)
     
  • FTSE 100

    7,222.82
    +18.27 (+0.25%)
     
  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     

Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Aptorum Group Limited (NASDAQ: APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus.

  • Specifically, two additional cohorts (Cohort C & D) of the single ascending dose portion of the Phase 1 trial in healthy subjects have been completed with no serious adverse events observed.

  • No subjects were dropped out of the studies, and no serious adverse events were observed.

  • Additionally, no clinically relevant changes regarding vital signs, electrocardiogram, clinical laboratory test results and physical examinations were observed compared to baselines.

  • The single ascending dose is still ongoing to gain additional insights into the effect of food on bioavailability and pharmacokinetics.

  • On this basis, the company plans to proceed to the multiple ascending dose part in 3Q of 2021.

  • In May, the company completed two initial cohorts of the single-dose ascending dose portion of the Phase 1 trial.

  • Price Action: APM shares are up 4.64% at $3.16 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.